The prevalence and effects of treatments of rapidly progressive interstitial lung disease of dermatomyositis/polymyositis adults: A systematic review and meta-analysis

Wang, Hongli; Lv, Jiyang; He, Jianxing; Zhong, Yuchao; Cao, Siyang; Cai, Yueming; Wang, Qingwen

doi:10.1016/j.autrev.2023.103335

Cited by 8 publications

(2 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interstitial lung disease (ILD) in patients diagnosed with idiopathic inflammatory myositis (IIM) has a global prevalence of approximately 41% 2 . A recent meta‐analysis reported that the prevalence of RP‐ILD is 8.9%, with rates being higher in Asian populations—reaching up to 20% in some studies 3–5 . Although no consensus exists on the time frame for RP‐ILD, it is typically characterized by worsening symptoms, hypoxemia, and declines in radiological or lung function over 1–3 months 6–8 …”

Section: Figurementioning

confidence: 99%

“…It is crucial to acknowledge that different time frames (1 or 3 months) are used for defining RP‐ILD in different studies, which could lead to significant variability in the prevalence and outcomes of RP‐ILD in anti‐MDA5 DM‐ILD among studies 3–8 . This heterogeneity among studies highlights the pressing need for shared criteria for defining RP‐ILD.…”

Section: Figurementioning

confidence: 99%

See 1 more Smart Citation

Upfront combination therapy in anti‐melanoma differentiation‐associated gene 5 (MDA5) associated rapidly progressive interstitial lung disease

Tseng

2024

Int J of Rheum Dis

View full text Add to dashboard Cite

Section: Figurementioning

confidence: 99%

Section: Figurementioning

confidence: 99%

Upfront combination therapy in anti‐melanoma differentiation‐associated gene 5 (MDA5) associated rapidly progressive interstitial lung disease

Tseng

2024

Int J of Rheum Dis

View full text Add to dashboard Cite

Emergencies in inflammatory rheumatic diseases

Auyezkhankyzy,

Izekenova,

Kocyigit

2024

Rheumatol Int

View full text Add to dashboard Cite

Inflammatory rheumatic diseases (IRDs), encompassing a broad spectrum of chronic disorders, typically necessitate prolonged therapeutic intervention. Nevertheless, these diseases can sometimes manifest as severe emergencies requiring prompt and extensive medical intervention. Urgent intervention is essential for effectively recognizing and managing these situations, as they have the potential to be life-threatening and can result in severe morbidity and mortality. Emergencies in IRDs can occur with different frequencies and manifestations, including nervous system issues, severe infections, thrombosis-emboli, renal crises, gastrointestinal issues, and cardiovascular events. The fact that these events can occur across different IRDs underscores the necessity for heightened awareness and readiness among healthcare professionals. The pathophysiologic mechanisms that cause rheumatic emergencies are complex and involve multiple factors. These emergencies frequently arise due to the interplay between the inflammatory characteristics of rheumatic diseases and different systemic triggers. Early detection and treatment can have a substantial impact on an individual’s prognosis in cases of severe and life-threatening disorders that require prompt recognition. Rapid decision-making and urgent care are required to effectively address rheumatic emergencies, as well as the implementation of a diagnostic flowchart. This article provides an overview of the emergencies linked to IRDs, classifying and assessing them individually. This article aims to enhance healthcare professionals’ knowledge and awareness of critical situations by examining current recommendations and pathophysiological information. Implementing standardized diagnostic and treatment methods, providing patient education, and conducting continuing research into the underlying mechanisms are essential for enhancing the management of these critical situations and improving patient outcomes.

show abstract

Soluble CXCL16 is a prognostic biomarker associated with rapidly progressive interstitial lung disease complicated with dermatomyositis

Li,

Han,

et al. 2024

Seminars in Arthritis and Rheumatism

View full text Add to dashboard Cite

The prevalence and effects of treatments of rapidly progressive interstitial lung disease of dermatomyositis/polymyositis adults: A systematic review and meta-analysis

Cited by 8 publications

References 57 publications

Upfront combination therapy in anti‐melanoma differentiation‐associated gene 5 (MDA5) associated rapidly progressive interstitial lung disease

Upfront combination therapy in anti‐melanoma differentiation‐associated gene 5 (MDA5) associated rapidly progressive interstitial lung disease

Emergencies in inflammatory rheumatic diseases

Soluble CXCL16 is a prognostic biomarker associated with rapidly progressive interstitial lung disease complicated with dermatomyositis

Contact Info

Product

Resources

About